BeiGene beefs up PD-1 da­ta with pos­i­tive PhI­II re­sults for tislelizum­ab, this time in metasta­t­ic NSCLC

BeiGene has been an­gling to dis­rupt the PD-1 mar­ket for quite some time, and on Tues­day ap­peared to take one step clos­er.

The Chi­nese biotech an­nounced that a Phase III study eval­u­at­ing its PD-(L)1 check­point in­hibitor tislelizum­ab in metasta­t­ic non-small cell lung can­cer met its pri­ma­ry end­point of over­all sur­vival. BeiGene didn’t pro­vide num­bers or p-val­ues with Tues­day’s re­sults, but not­ed that this was the drug’s third Phase III in NSCLC to go pos­i­tive at the in­ter­im read­out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER